Drug Approval | October 18, 2022
Zydus receives tentative approval from USFDA for Roflumilast tablets
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The hospital has taken a huge step by offering “Titli-palliative care services at home” to provide curative, restorative, and life-prolonging treatment to seriously ill children
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
The move will add new global talent to Cytel’s Strategic Consulting group
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
Subscribe To Our Newsletter & Stay Updated
